Overview

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

Status:
Unknown status
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
30 patients with advanced melanoma will receive apatinib plus Temozolomide as maintenance therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Cancer Hospital
Treatments:
Apatinib
Dacarbazine
Temozolomide